Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling
Authors
Keywords
-
Journal
CTS-Clinical and Translational Science
Volume 9, Issue 1, Pages 43-50
Publisher
Wiley
Online
2016-01-21
DOI
10.1111/cts.12384
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Exploratory Modeling and Simulation to Support Development of Motesanib in Asian Patients With Non–Small Cell Lung Cancer Based on MONET1 Study Results
- (2014) L Claret et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling
- (2013) M L Maitland et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Harnessing Technology to Improve Clinical Trials: Study of Real-Time Informatics to Collect Data, Toxicities, Image Response Assessments, and Patient-Reported Outcomes in a Phase II Clinical Trial
- (2013) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer
- (2013) Laurent Claret et al. JOURNAL OF CLINICAL ONCOLOGY
- Why RECIST Works and Why It Should Stay--Counterpoint
- (2012) A. T. Fojo et al. CANCER RESEARCH
- RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox--Point
- (2012) M. R. Sharma et al. CANCER RESEARCH
- Tumor Burden Modeling Versus Progression-Free Survival for Phase II Decision Making
- (2012) L. D. Kaiser CLINICAL CANCER RESEARCH
- Analyzing the Pivotal Trial That Compared Sunitinib and IFN- in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
- (2012) W. D. Stein et al. CLINICAL CANCER RESEARCH
- Simulations Using a Drug–Disease Modeling Framework and Phase II Data Predict Phase III Survival Outcome in First-Line Non–Small-Cell Lung Cancer
- (2012) L Claret et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical trials in the era of personalized oncology
- (2011) Michael L. Maitland et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials
- (2011) M.-W. An et al. CLINICAL CANCER RESEARCH
- Analysis of tumor burden versus progression-free survival for Phase II decision making
- (2011) Jane Fridlyand et al. Contemporary Clinical Trials
- A Time to Keep and a Time to Cast Away Categories of Tumor Response
- (2011) Michael L. Maitland et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
- (2010) W. D. Stein et al. CLINICAL CANCER RESEARCH
- A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology
- (2010) Rene Bruno et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Randomized Phase II Trials: Time for a New Era in Clinical Trial Design
- (2010) Sumithra J. Mandrekar et al. Journal of Thoracic Oncology
- Novel Designs and End Points for Phase II Clinical Trials
- (2009) A. A. Adjei et al. CLINICAL CANCER RESEARCH
- Alternate Endpoints for Screening Phase II Studies
- (2009) N. Dhani et al. CLINICAL CANCER RESEARCH
- Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
- (2009) Y Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies
- (2009) R Bruno et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials
- (2008) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
- Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy—Cancer and Leukemia Group B Trial 30203
- (2008) Martin J. Edelman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303)
- (2008) Antonius A. Miller et al. Journal of Thoracic Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now